Badanie porównujące skuteczność różnych dawek leku NN0519-0130 Obniżenie poziomu cukru we krwi u osób chorych na cukrzycę typu 2
Badanie bezpieczeństwa i skuteczności podawania raz w tygodniu NNC0519-0130 u osób chorych na cukrzycę typu 2 – badanie ustalające dawkę
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Free State
-
Bloemfontein, Free State, Afryka Południowa, 9301
- Josha Research
-
-
Gauteng
-
Johannesburg, Gauteng, Afryka Południowa, 2013
- Wits Bara Clinical Trial Site
-
Midrand, Gauteng, Afryka Południowa, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Afryka Południowa, 4450
- Dr Pillay's Rooms
-
eMkhomazi, KwaZulu-Natal, Afryka Południowa, 4170
- Dr T Padayachee
-
-
-
-
New South Wales
-
Campbelltown, New South Wales, Australia, 2560
- Campbelltown Hospital
-
Macquarie Park, New South Wales, Australia, 2109
- Macquarie University - Clinical Trials Unit
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Australia, 2148
- Western Endocrine Blacktown
-
Sydney, New South Wales, Australia, 2148
- Roger Chih Yu Chen
-
Wollongong, New South Wales, Australia, 2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya, Queensland, Australia, 4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook, Queensland, Australia, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Australia, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell, Victoria, Australia, 3124
- Emeritus Research Melbourne
-
Heidelberg Heights, Victoria, Australia, 3081
- Austin Health, Metabolic Disorders Centre
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle, Western Australia, Australia, 6160
- Fremantle Hospital
-
-
-
-
-
Bengaluru, Indie, 560054
- MS Ramaiah
-
New Delhi, Indie, 110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore, Karnataka, Indie, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi, Kerala, Indie, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, Indie, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai, Maharashtra, Indie, 400012
- Seth GS Medical College & KEM Hospital
-
Pune, Maharashtra, Indie, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur, Rajasthan, Indie, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Indie, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, Indie, 500082
- Diabetes Research Center, Hyderabad
-
-
-
-
-
Chiba, Japonia, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama, Japonia, 340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo, Japonia, 104-0031
- Fukuwa Clinic
-
Tokyo, Japonia, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japonia, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
-
Québec, Kanada, G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna, British Columbia, Kanada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond, British Columbia, Kanada, V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria, British Columbia, Kanada, V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Kanada, L4N 7L3
- Centricity Research Barrie
-
Hamilton, Ontario, Kanada, L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia, Ontario, Kanada, N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto, Ontario, Kanada, M4G 3E8
- Centricity Research Toronto
-
Toronto, Ontario, Kanada, M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis, Quebec, Kanada, G6W 0M5
- Centricity Research Quebec City
-
Mirabel, Quebec, Kanada, J7J 2K8
- Centricity Research Mirabel
-
Montreal, Quebec, Kanada, H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent, Quebec, Kanada, H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
-
Seoul, Korea Południowa, 05505
- Asan Medical Center
-
Seoul, Korea Południowa, 01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul, Korea Południowa, 03181
- Kangbuk Samsung Hospital
-
Seoul, Korea Południowa, 02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea Południowa, 13620
- Seoul National University Bundang Hospital
-
-
-
-
California
-
Chula Vista, California, Stany Zjednoczone, 91911
- Velocity Clin Res-Chula Vista
-
Fresno, California, Stany Zjednoczone, 93720
- Valley Research
-
Inglewood, California, Stany Zjednoczone, 90301
- 310 Clinical Research
-
La Mesa, California, Stany Zjednoczone, 91942
- Velocity Clin Res San Diego
-
Lancaster, California, Stany Zjednoczone, 93534
- First Valley Med Grp Lancaster
-
Lomita, California, Stany Zjednoczone, 90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos, California, Stany Zjednoczone, 90720
- Pacific Clinical Studies
-
Los Angeles, California, Stany Zjednoczone, 90057
- Velocity Clinical Research Westlake
-
Montclair, California, Stany Zjednoczone, 91763
- Catalina Research Institute, LLC
-
San Diego, California, Stany Zjednoczone, 92123
- Artemis Insitute for Clin Res
-
Toluca Lake, California, Stany Zjednoczone, 91602
- Med Partners, Inc.
-
Torrance, California, Stany Zjednoczone, 90505
- UCLA Health Southbay Endocrine
-
Tustin, California, Stany Zjednoczone, 92780
- University Clin Investigators
-
Walnut Creek, California, Stany Zjednoczone, 94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater, Florida, Stany Zjednoczone, 33756
- Innovative Research of W Florida Inc.
-
Clearwater, Florida, Stany Zjednoczone, 33756
- Innovative Research of W FL
-
Miami, Florida, Stany Zjednoczone, 33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus, Georgia, Stany Zjednoczone, 31904
- Centricity Research
-
-
Idaho
-
Blackfoot, Idaho, Stany Zjednoczone, 83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria, Illinois, Stany Zjednoczone, 61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City, Iowa, Stany Zjednoczone, 52242
- University of Iowa
-
-
Maryland
-
Columbia, Maryland, Stany Zjednoczone, 21045
- Centennial Medical Group
-
Oxon Hill, Maryland, Stany Zjednoczone, 20745
- MD Medical Research
-
Rockville, Maryland, Stany Zjednoczone, 20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield, Missouri, Stany Zjednoczone, 65807
- Clinvest Research
-
-
Montana
-
Butte, Montana, Stany Zjednoczone, 59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln, Nebraska, Stany Zjednoczone, 68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89148
- Palm Research Center Inc-Vegas
-
Las Vegas, Nevada, Stany Zjednoczone, 89109
- Excel Clinical Network
-
-
New York
-
Binghamton, New York, Stany Zjednoczone, 13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro, North Carolina, Stany Zjednoczone, 27408
- PharmQuest Life Sciences LLC
-
Wilmington, North Carolina, Stany Zjednoczone, 28401
- Accellacare Wilmington
-
-
Ohio
-
Canton, Ohio, Stany Zjednoczone, 44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati, Ohio, Stany Zjednoczone, 45242
- Velocity Clin Res_Cincinnati
-
Cincinnati, Ohio, Stany Zjednoczone, 45246
- Velocity Clinical Research Springdale
-
Dayton, Ohio, Stany Zjednoczone, 45439
- Providence Health Partners Ctr
-
Maumee, Ohio, Stany Zjednoczone, 43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass, Oregon, Stany Zjednoczone, 97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19114
- Tristar Clin Investigations, PC
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15243
- Preferred Primary Care Physicians Inc.
-
Uniontown, Pennsylvania, Stany Zjednoczone, 15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene, Texas, Stany Zjednoczone, 79606
- Velocity Clinical Research Abilene
-
Austin, Texas, Stany Zjednoczone, 78759
- Velocity Clin Res Austin
-
Dallas, Texas, Stany Zjednoczone, 75390
- UT Southwestern Med Center
-
Dallas, Texas, Stany Zjednoczone, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, Stany Zjednoczone, 75230
- Zenos Clinical research
-
Forney, Texas, Stany Zjednoczone, 75126
- Care United Research, LLC
-
Houston, Texas, Stany Zjednoczone, 77004
- Endocrine Associates Houston
-
Houston, Texas, Stany Zjednoczone, 77043
- Biopharma Informatic_Houston
-
Irving, Texas, Stany Zjednoczone, 75039
- Tekton Research
-
Lewisville, Texas, Stany Zjednoczone, 75057
- Epic Clinical Research
-
Shavano Park, Texas, Stany Zjednoczone, 78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke, Virginia, Stany Zjednoczone, 22015
- Burke Internal Medicine & Research
-
Newport News, Virginia, Stany Zjednoczone, 23606
- TPMG Clinical Research
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparator placebo: Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperymentalny: Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparator placebo: Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperymentalny: Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparator placebo: Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperymentalny: Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparator placebo: Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperymentalny: Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparator placebo: Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Aktywny komparator: Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Ramy czasowe: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Ramy czasowe: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Ramy czasowe: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Ramy czasowe: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Ramy czasowe: From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- NN9541-4945
- U1111-1291-9196 (Inny identyfikator: World Health Organization (WHO))
- jRCT2031230704 (Identyfikator rejestru: JRCT)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .